Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 4-Minute chat rival a Dietitian's hour for heart health?

NCT ID NCT05772325

Disease control Sponsor: Diakonhjemmet Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether a short, standardized 4-minute heart-healthy talk is as effective as a full 60-minute personalized session with a dietitian for lowering LDL cholesterol and improving diet. Participants are adults aged 30–80 with rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis who have an elevated risk of heart disease. The goal is to see if a quick, easy approach can help manage heart disease risk in people with inflammatory joint conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dietary counseling
What this could lead to
If it works, this could show that simple, brief dietary advice is as effective as personalized counseling for improving heart health in people with inflammatory joint disease.
What could go wrong
This is a small study with only 70 participants, so results may not apply to everyone. Dietary changes can be hard to maintain, and the brief advice may not be enough to produce lasting improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with either RA, PsA, or AS, between 30-80 years with an increased risk of future CVD, estimated using the CVD risk calculator. i.e. any risk \> 5 -10 % predicted by Systematic Coronary Risk Evaluation (SCORE2) algorithm. Also, patients with very high risk (predicted risk \>10%) as well as established atherosclerotic CVD (ASCVD) including previous myocardial infarction, coronary intervention (coronary artery bypass grafting or percutaneous coronary intervention), transient ischemic attack/strokes, atherosclerotic diseases of arteries as in the carotid artery or peripheral arterial disease (PAD) will also be included. Exclusion Criteria: 1. Heart failure with systolic EF\<40% 2. Kidney failure with GFR \< 35 3. Liver failure 4. Mental disorder rendering the patient unable to comply with the protocol 5. Being able to speak the language of the country 6. Reduced cognitive function 7. Substance abuse 8. Recent initiation or change in doses of lipid-lowering therapy or weight loss medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis psoriatic arthritis rheumatoid arthritis Spondylarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis Rheumatoid arthritis Spondyloarthritis

Contacts and locations

Locations

  • Diakonhjemmet Hospital

    Oslo, 0370, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.